A Randomized, Double-Blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

A Randomized, Double-Blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) zhoum55 Fri, 10/09/2026 - 05:23 Brentuximab vedotin Brentuximab vedotin PHASE III Thu, 08/20/2020 - 12:00 Fri, 01/23/2026 - 12:00 NCT04404283 C5691003 Public Disclosure Synopsis.pdf (143.34 KB) N https://clinicaltrials.gov/study/NCT04404283?term=C5691003&viewType=Card&rank=1 C5691003 (SGN35-031)